{
  "id": "vasculitic-neuropathy",
  "title": "Vasculitic Neuropathy",
  "version": "1.2",
  "icd10": [
    "** G63 (Polyneuropathy in diseases classified elsewhere)",
    "M31.7 (Microscopic polyangiitis)",
    "M30.0 (Polyarteritis nodosa)",
    "M31.30 (Wegener granulomatosis without renal involvement — GPA)",
    "M31.31 (Wegener granulomatosis with renal involvement — GPA)",
    "M30.1 (Polyarteritis with lung involvement — EGPA)",
    "M35.2 (Behçet disease)"
  ],
  "scope": "** Evaluation and management of peripheral neuropathy caused by vasculitis of the vasa nervorum. Covers systemic vasculitis (PAN, GPA, MPA, EGPA, cryoglobulinemic), non-systemic vasculitic neuropathy (NSVN), and connective tissue disease-associated (RA, SLE, Sjögren). Includes diagnostic workup, nerve/muscle biopsy guidance, immunosuppressive treatment, and pain management. Excludes CNS vasculitis (covered separately).",
  "notes": [],
  "sections": {
    "Laboratory Workup": {
      "Core Labs (All Patients)": [
        {
          "item": "CBC with differential (CPT 85025)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT",
          "rationale": "Eosinophilia (EGPA); anemia of chronic disease; leukocytosis; thrombocytosis (inflammation)",
          "target": "Normal; eosinophils >1500 suggests EGPA"
        },
        {
          "item": "CMP (CPT 80053)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT",
          "rationale": "Renal function (renal vasculitis); hepatic function; electrolytes",
          "target": "Normal creatinine and LFTs"
        },
        {
          "item": "ESR (CPT 85652)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT",
          "rationale": "Inflammatory marker; often markedly elevated in active vasculitis",
          "target": "Normal (<20 mm/hr); elevated supports active vasculitis"
        },
        {
          "item": "CRP (CPT 86200)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT",
          "rationale": "Acute-phase reactant; correlates with disease activity",
          "target": "Normal (<0.5 mg/dL)"
        },
        {
          "item": "ANCA screen with MPO and PR3 antibodies (CPT 86021, 86022)",
          "ED": "URGENT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT",
          "rationale": "GPA (PR3+), MPA (MPO+), EGPA (MPO+ or negative); critical for classification",
          "target": "Negative; positive directs classification"
        },
        {
          "item": "Urinalysis with microscopy (CPT 81001)",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT",
          "rationale": "Renal vasculitis (hematuria, proteinuria, RBC casts); critical for systemic involvement",
          "target": "Normal; no active sediment"
        },
        {
          "item": "BUN / Creatinine",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT",
          "rationale": "Renal involvement screening; rapidly progressive glomerulonephritis (RPGN)",
          "target": "Normal creatinine"
        },
        {
          "item": "ANA (CPT 86235)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Connective tissue disease screen (SLE, Sjögren, RA)",
          "target": "Negative"
        },
        {
          "item": "Hepatitis B surface antigen and antibody (CPT 87340)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "PAN strongly associated with hepatitis B; required before immunosuppression",
          "target": "Negative"
        },
        {
          "item": "Hepatitis C antibody (CPT 86803)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Cryoglobulinemic vasculitis associated with HCV",
          "target": "Negative"
        }
      ],
      "Extended Labs": [
        {
          "item": "Complement C3 and C4 (CPT 83883, 83885)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Low complement in cryoglobulinemic vasculitis, SLE, and hypocomplementemic urticarial vasculitis",
          "target": "Normal"
        },
        {
          "item": "Cryoglobulins (CPT 86157)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Cryoglobulinemic vasculitis; must be drawn warm and processed at 37°C",
          "target": "Negative"
        },
        {
          "item": "Rheumatoid factor (CPT 82785)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "RA-associated vasculitis; also elevated in cryoglobulinemia",
          "target": "Negative"
        },
        {
          "item": "Anti-dsDNA (CPT 86038)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "SLE-associated vasculitic neuropathy",
          "target": "Negative"
        },
        {
          "item": "SSA/SSB antibodies",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Sjögren syndrome-associated vasculitic neuropathy",
          "target": "Negative"
        },
        {
          "item": "Serum protein electrophoresis / immunofixation",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Monoclonal gammopathy; amyloidosis; cryoglobulinemia evaluation",
          "target": "No monoclonal protein"
        },
        {
          "item": "Serum free light chains",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "AL amyloidosis masquerading as vasculitis",
          "target": "Normal kappa/lambda ratio"
        },
        {
          "item": "HIV antibody",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "HIV-associated vasculitis; PAN-like syndrome",
          "target": "Negative"
        },
        {
          "item": "RPR/VDRL (CPT 86592)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Syphilitic vasculitis affecting peripheral nerves",
          "target": "Nonreactive"
        },
        {
          "item": "Quantitative immunoglobulins (IgG, IgA, IgM)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Baseline before immunosuppression; IgA deficiency before IVIg",
          "target": "Normal"
        },
        {
          "item": "Anti-CCP antibodies",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "RA-associated vasculitis confirmation",
          "target": "Negative"
        },
        {
          "item": "IgE level",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Markedly elevated in EGPA; correlates with disease activity",
          "target": "Normal"
        }
      ],
      "Rare/Specialized": [
        {
          "item": "Nerve and muscle biopsy (sural nerve + gastrocnemius or superficial peroneal + peroneus brevis)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Gold standard for vasculitic neuropathy diagnosis; demonstrates necrotizing vasculitis of vasa nervorum",
          "target": "No vasculitis; positive = fibrinoid necrosis, inflammatory infiltrate in vessel walls"
        },
        {
          "item": "Urine protein/creatinine ratio or 24-hr urine protein",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Quantify renal involvement; nephrotic-range proteinuria suggests glomerular disease",
          "target": "<0.2 mg/mg (normal)"
        },
        {
          "item": "Anti-GBM antibodies",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Anti-GBM disease with pulmonary-renal syndrome",
          "target": "Negative"
        },
        {
          "item": "Eosinophil count (absolute)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Eosinophilia >1500/μL strongly suggests EGPA",
          "target": "<500/μL"
        },
        {
          "item": "Paraneoplastic antibody panel",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-",
          "rationale": "Paraneoplastic vasculitis if malignancy suspected",
          "target": "Negative"
        },
        {
          "item": "ACE level",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "rationale": "Sarcoidosis with granulomatous neuropathy mimicking vasculitis",
          "target": "Normal"
        }
      ]
    },
    "Imaging & Studies": {
      "Essential Studies": [
        {
          "item": "NCS/EMG (CPT 95907-95913, 95860-95870)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "timing": "Within days of presentation; characterize neuropathy pattern",
          "target": "Asymmetric, multifocal axonal neuropathy (mononeuritis multiplex pattern); reduced SNAPs and CMAPs in non-contiguous nerves",
          "contraindications": "None"
        },
        {
          "item": "Chest X-ray",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT",
          "timing": "Screen for pulmonary involvement (GPA, EGPA, MPA)",
          "target": "Normal; nodules or infiltrates suggest pulmonary vasculitis",
          "contraindications": "None"
        },
        {
          "item": "CT chest with contrast (CPT 71260)",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "timing": "Pulmonary nodules, cavitary lesions (GPA), infiltrates (EGPA), hemorrhage (MPA)",
          "target": "Normal; abnormal = nodules, cavitary lesions, ground-glass opacities",
          "contraindications": "Contrast allergy; renal insufficiency"
        }
      ],
      "Extended Studies": [
        {
          "item": "CT abdomen/pelvis with contrast (CPT 74178)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "timing": "PAN: mesenteric/renal artery aneurysms; systemic vasculitis staging",
          "target": "Normal; microaneurysms suggest PAN",
          "contraindications": "Contrast allergy; renal insufficiency"
        },
        {
          "item": "MRI peripheral nerves (neurography)",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-",
          "timing": "Identify nerve inflammation, enlargement, or enhancement; guide biopsy site",
          "target": "Normal signal; abnormal = T2 hyperintensity, enhancement",
          "contraindications": "MRI-incompatible devices"
        },
        {
          "item": "CT/MR angiography (mesenteric/renal arteries)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "timing": "PAN: medium-vessel aneurysms and stenoses; definitive for medium-vessel vasculitis",
          "target": "Normal; microaneurysms and irregular stenoses suggest PAN",
          "contraindications": "Contrast allergy; renal insufficiency"
        },
        {
          "item": "Echocardiogram",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "timing": "Cardiac involvement in EGPA (endomyocardial fibrosis, pericarditis); endocarditis exclusion",
          "target": "Normal; abnormal wall motion or pericardial effusion",
          "contraindications": "None"
        },
        {
          "item": "MRI brain with contrast (CPT 70553)",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-",
          "timing": "If CNS vasculitis suspected concurrently (headache, encephalopathy, stroke-like episodes)",
          "target": "Normal; abnormal = multifocal white matter lesions, infarcts",
          "contraindications": "MRI-incompatible devices"
        }
      ],
      "Rare/Specialized": [
        {
          "item": "PET/CT",
          "ED": "-",
          "HOSP": "-",
          "OPD": "EXT",
          "ICU": "-",
          "timing": "Large-vessel vasculitis; occult malignancy with paraneoplastic vasculitis; systemic disease staging",
          "target": "No FDG-avid lesions",
          "contraindications": "Pregnancy; uncontrolled diabetes"
        },
        {
          "item": "Conventional angiography (mesenteric/renal)",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "-",
          "ICU": "-",
          "timing": "Gold standard for PAN if non-invasive imaging equivocal",
          "target": "Normal; microaneurysms are pathognomonic for PAN",
          "contraindications": "Renal insufficiency; contrast allergy; coagulopathy"
        },
        {
          "item": "MRI spine with contrast",
          "ED": "-",
          "HOSP": "EXT",
          "OPD": "EXT",
          "ICU": "-",
          "timing": "If concurrent myelopathy suspected (rare)",
          "target": "Normal",
          "contraindications": "MRI-incompatible devices"
        },
        {
          "item": "Skin biopsy (punch biopsy of purpuric lesion)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-",
          "timing": "Leukocytoclastic vasculitis; IgA vasculitis; cryoglobulinemic vasculitis",
          "target": "No vasculitis; positive = neutrophilic infiltrate, fibrinoid necrosis",
          "contraindications": "Anticoagulation (relative)"
        }
      ]
    },
    "Treatment": {
      "Acute/Emergent": [
        {
          "item": "IV Methylprednisolone",
          "route": "IV",
          "indication": "Acute severe vasculitic neuropathy with rapidly progressive weakness; renal crisis; pulmonary hemorrhage",
          "dosing": {
            "doseOptions": [
              {
                "text": "1000 mg",
                "orderSentence": "IV Methylprednisolone 1000 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "1000 mg IV daily for 3-5 days; infuse over 1 hour; followed by oral prednisone taper",
            "orderSentence": "IV Methylprednisolone 1000 mg IV"
          },
          "contraindications": "Active untreated infection; uncontrolled diabetes; GI bleed",
          "monitoring": "Blood glucose QID; BP; mood/sleep; GI symptoms; electrolytes",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        },
        {
          "item": "Plasma exchange (PLEX)",
          "route": "Apheresis",
          "indication": "Rapidly progressive renal failure (RPGN); pulmonary hemorrhage in AAV; cryoglobulinemic vasculitis with organ-threatening disease",
          "dosing": {
            "doseOptions": [
              {
                "text": "1-1.5 plasma volumes",
                "orderSentence": "Plasma exchange (PLEX) 1-1.5 plasma volumes Apheresis"
              }
            ],
            "route": "Apheresis",
            "instructions": "5-7 exchanges over 10-14 days; 1-1.5 plasma volumes per exchange; albumin replacement",
            "orderSentence": "Plasma exchange (PLEX) 1-1.5 plasma volumes Apheresis"
          },
          "contraindications": "Hemodynamic instability; severe coagulopathy; poor vascular access",
          "monitoring": "Coagulation studies; electrolytes; fibrinogen; calcium; BP; hemodynamic monitoring",
          "ED": "-",
          "HOSP": "URGENT",
          "OPD": "-",
          "ICU": "URGENT"
        },
        {
          "item": "Prednisone (oral induction)",
          "route": "PO",
          "indication": "First-line for all vasculitic neuropathy; induction following IV pulse steroids",
          "dosing": {
            "doseOptions": [
              {
                "text": "60 mg daily",
                "orderSentence": "Prednisone (oral induction) 60 mg daily PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 1 mg/kg/day (max 80 mg); taper by 10 mg q2wk to 40 mg, then by 5 mg q2wk; target prednisone-free or ≤5 mg/day by 6-12 months",
            "orderSentence": "Prednisone (oral induction) 60 mg daily PO"
          },
          "contraindications": "Active untreated infection; uncontrolled diabetes; GI bleed; psychosis",
          "monitoring": "Blood glucose; BP; bone density; mood; weight; HbA1c; PPI for GI protection",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Acetaminophen",
          "route": "PO",
          "indication": "Acute pain; musculoskeletal pain; fever in setting of vasculitis",
          "dosing": {
            "doseOptions": [
              {
                "text": "650-1000 mg",
                "orderSentence": "Acetaminophen 650-1000 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "650-1000 mg PO q6h PRN; max 4 g/day (2 g/day if hepatic impairment)",
            "orderSentence": "Acetaminophen 650-1000 mg PO"
          },
          "contraindications": "Severe hepatic disease; allergy",
          "monitoring": "LFTs if prolonged use",
          "ED": "STAT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        }
      ],
      "Symptomatic Treatments": [
        {
          "item": "Gabapentin",
          "route": "PO",
          "indication": "Neuropathic pain from vasculitic nerve damage (first-line)",
          "dosing": {
            "doseOptions": [
              {
                "text": "300 mg",
                "orderSentence": "Gabapentin 300 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 300 mg qHS; titrate by 300 mg q1-3d; target 900-1800 mg TID; max 3600 mg/day divided TID",
            "orderSentence": "Gabapentin 300 mg PO"
          },
          "contraindications": "Severe renal impairment (dose adjust per CrCl: CrCl 30-59: max 900-1400 mg/day; CrCl 15-29: max 600 mg/day; CrCl <15: max 300 mg/day)",
          "monitoring": "Sedation; dizziness; edema; renal function for dose adjustment",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Pregabalin",
          "route": "PO",
          "indication": "Neuropathic pain; alternative first-line to gabapentin",
          "dosing": {
            "doseOptions": [
              {
                "text": "75 mg",
                "orderSentence": "Pregabalin 75 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 75 mg BID; increase to 150 mg BID after 1 week; max 600 mg/day",
            "orderSentence": "Pregabalin 75 mg PO"
          },
          "contraindications": "Severe renal impairment (dose adjust); angioedema history",
          "monitoring": "Sedation; dizziness; weight gain; edema; renal function",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "ROUTINE"
        },
        {
          "item": "Duloxetine",
          "route": "PO",
          "indication": "Neuropathic pain (first-line); concomitant depression; dual action SNRI",
          "dosing": {
            "doseOptions": [
              {
                "text": "30 mg",
                "orderSentence": "Duloxetine 30 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 30 mg daily x 1 week; increase to 60 mg daily; max 120 mg/day for pain",
            "orderSentence": "Duloxetine 30 mg PO"
          },
          "contraindications": "Concurrent MAOIs; uncontrolled narrow-angle glaucoma; severe renal impairment (GFR <30); severe hepatic impairment",
          "monitoring": "BP; hepatic function; serotonin syndrome signs; discontinuation symptoms if stopped abruptly",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Amitriptyline",
          "route": "PO",
          "indication": "Neuropathic pain (second-line); insomnia benefit",
          "dosing": {
            "doseOptions": [
              {
                "text": "10 mg",
                "orderSentence": "Amitriptyline 10 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 10-25 mg qHS; titrate by 10-25 mg q1-2wk; max 150 mg qHS",
            "orderSentence": "Amitriptyline 10 mg PO"
          },
          "contraindications": "Recent MI; cardiac conduction abnormalities; concurrent MAOIs; urinary retention; narrow-angle glaucoma; elderly (anticholinergic burden)",
          "monitoring": "ECG if dose >100 mg/day; anticholinergic effects; sedation; weight gain",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Nortriptyline",
          "route": "PO",
          "indication": "Neuropathic pain (second-line); better tolerated TCA than amitriptyline",
          "dosing": {
            "doseOptions": [
              {
                "text": "10 mg",
                "orderSentence": "Nortriptyline 10 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 10-25 mg qHS; increase by 10-25 mg q1-2wk; max 150 mg qHS",
            "orderSentence": "Nortriptyline 10 mg PO"
          },
          "contraindications": "Recent MI; cardiac conduction abnormalities; concurrent MAOIs; urinary retention; narrow-angle glaucoma",
          "monitoring": "ECG if dose >100 mg/day; fewer anticholinergic effects than amitriptyline",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Carbamazepine",
          "route": "PO",
          "indication": "Neuropathic pain refractory to first-line agents; lancinating pain",
          "dosing": {
            "doseOptions": [
              {
                "text": "100 mg",
                "orderSentence": "Carbamazepine 100 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 100 mg BID; titrate by 100-200 mg q1wk; max 1200 mg/day; check HLA-B*1502 in at-risk populations before starting",
            "orderSentence": "Carbamazepine 100 mg PO"
          },
          "contraindications": "Bone marrow suppression; AV block; concurrent MAOIs; porphyria; HLA-B*1502 positive",
          "monitoring": "CBC q2wk x 2 months then q3mo; LFTs; sodium (SIADH risk); drug levels; rash (SJS risk)",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Oxcarbazepine",
          "route": "PO",
          "indication": "Neuropathic pain; lancinating pain; alternative to carbamazepine with better tolerability",
          "dosing": {
            "doseOptions": [
              {
                "text": "300 mg",
                "orderSentence": "Oxcarbazepine 300 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 300 mg BID; increase by 300 mg every 3 days; max 1200 mg BID",
            "orderSentence": "Oxcarbazepine 300 mg PO"
          },
          "contraindications": "Hypersensitivity to carbamazepine",
          "monitoring": "Sodium (hyponatremia risk); HLA-B*1502 screening in at-risk populations",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Lidocaine 5% patch",
          "route": "Transdermal",
          "indication": "Localized neuropathic pain",
          "dosing": {
            "doseOptions": [
              {
                "text": "N/A",
                "orderSentence": "Lidocaine 5% patch N/A Transdermal"
              }
            ],
            "route": "Transdermal",
            "instructions": "Apply 1-3 patches to painful area for 12 hours on, 12 hours off",
            "orderSentence": "Lidocaine 5% patch N/A Transdermal"
          },
          "contraindications": "Severe hepatic impairment; application to broken skin",
          "monitoring": "Minimal systemic absorption; local irritation",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Tramadol",
          "route": "PO",
          "indication": "Moderate neuropathic pain (adjunct; third-line)",
          "dosing": {
            "doseOptions": [
              {
                "text": "50 mg",
                "orderSentence": "Tramadol 50 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 50 mg q6h PRN; may use ER 100 mg daily; max 400 mg/day",
            "orderSentence": "Tramadol 50 mg PO"
          },
          "contraindications": "Seizure disorder; concurrent MAOIs; concurrent SSRIs (serotonin syndrome)",
          "monitoring": "Serotonin syndrome; seizures; dependence (Schedule IV)",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Morphine IV",
          "route": "IV",
          "indication": "Severe acute pain unresponsive to non-opioid agents",
          "dosing": {
            "doseOptions": [
              {
                "text": "2-4 mg",
                "orderSentence": "Morphine IV 2-4 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "2-4 mg IV q3-4h PRN; use with caution; titrate to effect",
            "orderSentence": "Morphine IV 2-4 mg IV"
          },
          "contraindications": "Respiratory depression; paralytic ileus; concurrent MAOIs",
          "monitoring": "RR; SpO2; sedation scale; bowel function",
          "ED": "STAT",
          "HOSP": "URGENT",
          "OPD": "-",
          "ICU": "URGENT"
        },
        {
          "item": "Ondansetron",
          "route": "IV/PO",
          "indication": "Nausea/vomiting (steroid or cyclophosphamide-associated)",
          "dosing": {
            "doseOptions": [
              {
                "text": "4 mg",
                "orderSentence": "Ondansetron 4 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "4 mg IV/PO q6h PRN; max 16 mg/day",
            "orderSentence": "Ondansetron 4 mg IV"
          },
          "contraindications": "QT prolongation; severe hepatic impairment (max 8 mg/day)",
          "monitoring": "ECG if QT prolongation risk; constipation",
          "ED": "STAT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Omeprazole",
          "route": "PO",
          "indication": "GI protection during high-dose corticosteroid therapy",
          "dosing": {
            "doseOptions": [
              {
                "text": "20 mg",
                "orderSentence": "Omeprazole 20 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "20 mg daily while on corticosteroids; continue throughout steroid course",
            "orderSentence": "Omeprazole 20 mg PO"
          },
          "contraindications": "Hypersensitivity; concurrent rilpivirine",
          "monitoring": "Magnesium with prolonged use; B12 with long-term use",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Docusate sodium",
          "route": "PO",
          "indication": "Constipation (opioid or immobility-related)",
          "dosing": {
            "doseOptions": [
              {
                "text": "100 mg",
                "orderSentence": "Docusate sodium 100 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "100 mg BID; max 500 mg/day",
            "orderSentence": "Docusate sodium 100 mg PO"
          },
          "contraindications": "Intestinal obstruction",
          "monitoring": "Bowel function",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Senna",
          "route": "PO",
          "indication": "Constipation",
          "dosing": {
            "doseOptions": [
              {
                "text": "8.6-17.2 mg",
                "orderSentence": "Senna 8.6-17.2 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "8.6-17.2 mg qHS; max 34.4 mg/day",
            "orderSentence": "Senna 8.6-17.2 mg PO"
          },
          "contraindications": "Intestinal obstruction; acute abdominal pain",
          "monitoring": "Cramping; bowel function",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Trazodone",
          "route": "PO",
          "indication": "Insomnia with chronic pain",
          "dosing": {
            "doseOptions": [
              {
                "text": "25-50 mg",
                "orderSentence": "Trazodone 25-50 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 25-50 mg qHS; increase to 100-150 mg; max 200 mg qHS",
            "orderSentence": "Trazodone 25-50 mg PO"
          },
          "contraindications": "Concurrent MAOIs; QT prolongation",
          "monitoring": "QTc; priapism (rare); sedation",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Melatonin",
          "route": "PO",
          "indication": "Insomnia (adjunct; non-pharmacologic preferred)",
          "dosing": {
            "doseOptions": [
              {
                "text": "3-5 mg",
                "orderSentence": "Melatonin 3-5 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "3-5 mg qHS 30 minutes before bed",
            "orderSentence": "Melatonin 3-5 mg PO"
          },
          "contraindications": "None significant",
          "monitoring": "Generally well-tolerated",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Hydrocortisone (stress-dose)",
          "route": "IV",
          "indication": "Adrenal crisis prevention in patients on chronic corticosteroids presenting with acute illness, surgery, or hemodynamic instability",
          "dosing": {
            "doseOptions": [
              {
                "text": "100 mg",
                "orderSentence": "Hydrocortisone (stress-dose) 100 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "100 mg IV q8h; taper over 1-3 days as acute stressor resolves; resume home corticosteroid dose once stable",
            "orderSentence": "Hydrocortisone (stress-dose) 100 mg IV"
          },
          "contraindications": "Active adrenal insufficiency already being treated at higher doses",
          "monitoring": "BP; blood glucose; electrolytes; clinical response; taper to home steroid dose",
          "ED": "STAT",
          "HOSP": "STAT",
          "OPD": "-",
          "ICU": "STAT"
        }
      ],
      "Maintenance/Chronic Immunosuppression": [
        {
          "item": "Azathioprine",
          "route": "PO",
          "indication": "Maintenance after cyclophosphamide induction; steroid-sparing for NSVN",
          "dosing": {
            "doseOptions": [
              {
                "text": "50 mg",
                "orderSentence": "Azathioprine 50 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 50 mg daily; titrate to 2 mg/kg/day over 2-4 weeks; check TPMT before starting; duration 18-24 months minimum",
            "orderSentence": "Azathioprine 50 mg PO"
          },
          "contraindications": "TPMT deficiency (homozygous); concurrent allopurinol (severe toxicity); pregnancy (relative)",
          "monitoring": "CBC q2wk x 8 weeks then monthly; LFTs monthly x 3 then q3mo; TPMT genotype before initiation",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Methotrexate",
          "route": "PO",
          "indication": "Maintenance for GPA (non-severe); steroid-sparing; less nephrotoxic than azathioprine",
          "dosing": {
            "doseOptions": [
              {
                "text": "7.5 mg",
                "orderSentence": "Methotrexate 7.5 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 7.5-15 mg weekly; titrate by 2.5-5 mg q2-4wk; max 25 mg weekly; take with folic acid 1 mg daily (except methotrexate day)",
            "orderSentence": "Methotrexate 7.5 mg PO"
          },
          "contraindications": "Severe renal impairment (GFR <30); hepatic disease; pregnancy; significant pulmonary fibrosis",
          "monitoring": "CBC monthly; LFTs monthly; BUN/Cr monthly; pulmonary symptoms; mucositis",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Mycophenolate mofetil (CellCept)",
          "route": "PO",
          "indication": "Maintenance for AAV; alternative to azathioprine; renal-sparing",
          "dosing": {
            "doseOptions": [
              {
                "text": "500 mg",
                "orderSentence": "Mycophenolate mofetil (CellCept) 500 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "Start 500 mg BID; titrate to 1000-1500 mg BID over 2-4 weeks; max 3000 mg/day",
            "orderSentence": "Mycophenolate mofetil (CellCept) 500 mg PO"
          },
          "contraindications": "Pregnancy (teratogenic); severe GI disease; hypersensitivity",
          "monitoring": "CBC q2wk x 8 weeks then monthly; LFTs monthly; GI symptoms; pregnancy prevention",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Rituximab (maintenance)",
          "route": "IV",
          "indication": "Maintenance for AAV; prevents relapse; alternative to oral maintenance agents",
          "dosing": {
            "doseOptions": [
              {
                "text": "500 mg",
                "orderSentence": "Rituximab (maintenance) 500 mg IV"
              }
            ],
            "route": "IV",
            "instructions": "500 mg IV every 6 months; or 1000 mg IV every 6 months; continue for ≥24 months",
            "orderSentence": "Rituximab (maintenance) 500 mg IV"
          },
          "contraindications": "Active hepatitis B; severe active infection; PML risk",
          "monitoring": "CD19/CD20 counts q3-6mo; immunoglobulins q3-6mo; CBC; infection surveillance",
          "ED": "-",
          "HOSP": "-",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Low-dose prednisone (maintenance)",
          "route": "PO",
          "indication": "Ongoing low-dose steroid as bridge during taper; target prednisone-free state",
          "dosing": {
            "doseOptions": [
              {
                "text": "5 mg",
                "orderSentence": "Low-dose prednisone (maintenance) 5 mg PO"
              }
            ],
            "route": "PO",
            "instructions": "5-7.5 mg daily; taper by 1 mg/month toward discontinuation; PPI and calcium/vitamin D coadministration",
            "orderSentence": "Low-dose prednisone (maintenance) 5 mg PO"
          },
          "contraindications": "Active untreated infection; uncontrolled diabetes",
          "monitoring": "Blood glucose; BP; bone density annually; mood; weight; HbA1c",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Disease-Modifying Therapy (Induction Immunosuppression)": [
        {
          "item": "Cyclophosphamide (IV pulse)",
          "route": "IV",
          "indication": "Severe systemic vasculitis (AAV, PAN) with organ-threatening disease; induction therapy",
          "dosing": {
            "doseOptions": [
              {
                "text": "15 mg/kg",
                "orderSentence": "Cyclophosphamide (IV pulse) 15 mg/kg IV"
              }
            ],
            "route": "IV",
            "instructions": "15 mg/kg IV (max 1200 mg) q2wk x 3 doses, then q3wk x 3-6 doses; dose reduce for age >60 and renal impairment; hydrate and give MESNA",
            "orderSentence": "Cyclophosphamide (IV pulse) 15 mg/kg IV"
          },
          "pretreatment": "CBC, BUN/Cr, LFTs, urinalysis baseline; pregnancy test; fertility counseling; PCP prophylaxis with TMP-SMX",
          "contraindications": "Active infection; pregnancy; severe leukopenia (WBC <4000); prior cumulative dose >25 g",
          "monitoring": "CBC q1-2wk; urinalysis for hematuria; BUN/Cr; LFTs; cumulative dose tracking; fertility counseling",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Cyclophosphamide (oral daily)",
          "route": "PO",
          "indication": "Alternative to IV pulse; sometimes preferred in NSVN or when IV access limited",
          "dosing": {
            "doseOptions": [
              {
                "text": "2 mg/kg",
                "orderSentence": "Cyclophosphamide (oral daily) 2 mg/kg PO"
              }
            ],
            "route": "PO",
            "instructions": "2 mg/kg/day PO (round down to nearest 25 mg); max 200 mg/day; take in AM with liberal fluids; duration 3-6 months then switch to maintenance agent",
            "orderSentence": "Cyclophosphamide (oral daily) 2 mg/kg PO"
          },
          "pretreatment": "CBC, BUN/Cr, LFTs, urinalysis baseline; pregnancy test; fertility counseling; PCP prophylaxis with TMP-SMX",
          "contraindications": "Active infection; pregnancy; severe leukopenia (WBC <4000)",
          "monitoring": "CBC q1-2wk; urinalysis q1-2wk (microscopic hematuria = hemorrhagic cystitis); BUN/Cr; LFTs; cumulative dose",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Rituximab (induction)",
          "route": "IV",
          "indication": "AAV (GPA, MPA) induction; non-inferior to cyclophosphamide for AAV; preferred for relapsing disease or childbearing potential",
          "dosing": {
            "doseOptions": [
              {
                "text": "375 mg/m²",
                "orderSentence": "Rituximab (induction) 375 mg/m² IV"
              }
            ],
            "route": "IV",
            "instructions": "375 mg/m² IV weekly x 4 weeks; OR 1000 mg IV days 1 and 15; premedicate with acetaminophen, diphenhydramine, methylprednisolone 100 mg IV",
            "orderSentence": "Rituximab (induction) 375 mg/m² IV"
          },
          "pretreatment": "Hepatitis B serology; quantitative immunoglobulins; CD19/CD20 counts; pregnancy test; PML screening",
          "contraindications": "Active hepatitis B; severe active infection; PML risk; severe immunodeficiency",
          "monitoring": "CD19/CD20 counts q3mo; quantitative immunoglobulins q3mo; CBC; infection surveillance; hepatitis B monitoring",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ]
    },
    "Other Recommendations": {
      "Referrals & Consults": [
        {
          "item": "Rheumatology consultation for vasculitis classification, immunosuppression guidance, and long-term management of systemic vasculitis",
          "ED": "URGENT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Neurology/neuromuscular specialist for electrodiagnostic testing, nerve biopsy planning, and neuropathic pain management",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Nephrology consultation if renal involvement (hematuria, proteinuria, elevated creatinine) suggesting RPGN or renal vasculitis",
          "ED": "URGENT",
          "HOSP": "STAT",
          "OPD": "ROUTINE",
          "ICU": "STAT"
        },
        {
          "item": "Pulmonology if pulmonary involvement (nodules, hemorrhage, infiltrates) in GPA, MPA, or EGPA",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "URGENT"
        },
        {
          "item": "Surgery/pathology for combined nerve and muscle biopsy (sural + gastrocnemius preferred) to confirm vasculitic neuropathy diagnosis",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Physical therapy for strengthening, gait training, and fall prevention given motor weakness from nerve infarction",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Occupational therapy for hand function optimization and adaptive equipment given frequent upper extremity involvement",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Pain management referral for refractory neuropathic pain not responding to first-line agents",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Infectious disease consultation before initiating immunosuppression if hepatitis B/C positive or other active infection",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Patient Instructions": [
        {
          "item": "Return immediately if new weakness develops in a limb, new numbness or tingling appears, or existing weakness worsens rapidly (may indicate new nerve infarction requiring urgent treatment adjustment)",
          "ED": "STAT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Report fever, cough, or signs of infection promptly while on immunosuppression, as infection risk is significantly increased",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Do not stop corticosteroids or immunosuppressive medications abruptly without physician guidance, as this may cause disease flare or adrenal crisis",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Report blood in urine, decreased urine output, or swelling, which may indicate renal involvement requiring urgent evaluation",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Use fall precautions including assistive devices as needed given motor weakness from nerve damage",
          "ED": "URGENT",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ],
      "Lifestyle & Prevention": [
        {
          "item": "Bone density protection: calcium 1200 mg + vitamin D 1000 IU daily while on chronic corticosteroids; consider bisphosphonate if prednisone ≥7.5 mg daily for >3 months",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Pneumocystis prophylaxis with trimethoprim-sulfamethoxazole while on cyclophosphamide or high-dose steroids combined with other immunosuppression",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Annual influenza and pneumococcal vaccination; avoid live vaccines while immunosuppressed; COVID-19 vaccination per current guidelines; assess vaccination status during admission",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Smoking cessation to reduce vascular inflammation and improve overall cardiovascular health",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        },
        {
          "item": "Hepatitis B reactivation monitoring if HBcAb positive and receiving rituximab or other immunosuppression; antiviral prophylaxis as indicated",
          "ED": "-",
          "HOSP": "ROUTINE",
          "OPD": "ROUTINE",
          "ICU": "-"
        }
      ]
    }
  },
  "differential": [
    {
      "diagnosis": "Chronic inflammatory demyelinating polyneuropathy (CIDP)",
      "features": "Symmetric, proximal and distal weakness; demyelinating NCS pattern; elevated CSF protein; no systemic inflammation",
      "tests": "NCS (demyelinating vs axonal); CSF protein; nerve biopsy (demyelination vs vasculitis); inflammatory markers normal in CIDP"
    },
    {
      "diagnosis": "Multifocal motor neuropathy (MMN)",
      "features": "Pure motor; conduction block on NCS; anti-GM1 antibodies; no sensory loss; no systemic inflammation",
      "tests": "NCS (conduction block); anti-GM1 Ab; nerve biopsy (no vasculitis)"
    },
    {
      "diagnosis": "Sarcoidosis (neurosarcoidosis)",
      "features": "Granulomatous neuropathy; may mimic mononeuritis multiplex; hilar lymphadenopathy; elevated ACE",
      "tests": "ACE level; chest CT; nerve biopsy (non-caseating granulomas vs necrotizing vasculitis); bronchoscopy"
    },
    {
      "diagnosis": "Diabetic amyotrophy (diabetic lumbosacral radiculoplexus neuropathy)",
      "features": "Painful proximal leg weakness in diabetics; often asymmetric; microvasculitis on biopsy",
      "tests": "HbA1c; NCS/EMG (plexopathy pattern); nerve biopsy (microvasculitis without systemic vasculitis)"
    },
    {
      "diagnosis": "Amyloid neuropathy",
      "features": "Progressive sensory > motor neuropathy; autonomic involvement; may mimic vasculitis clinically",
      "tests": "Tissue biopsy with Congo red staining; SPEP/UPEP; free light chains; TTR gene testing"
    },
    {
      "diagnosis": "Lymphomatous neuropathy",
      "features": "Neurolymphomatosis; can mimic mononeuritis multiplex; B symptoms; nerve enlargement on MRI",
      "tests": "MRI neurography (nerve enlargement/enhancement); CSF cytology; PET/CT; nerve biopsy (lymphoma cells)"
    },
    {
      "diagnosis": "Hereditary neuropathy with liability to pressure palsies (HNPP)",
      "features": "Episodic multifocal neuropathy; family history; PMP22 deletion",
      "tests": "PMP22 deletion testing; NCS showing generalized slowing at entrapment sites; no inflammation"
    },
    {
      "diagnosis": "Leprosy (Hansen disease)",
      "features": "Asymmetric sensory > motor neuropathy in endemic areas; skin lesions; thickened nerves",
      "tests": "Skin biopsy (acid-fast bacilli); nerve biopsy; slit-skin smear; travel history"
    },
    {
      "diagnosis": "Paraneoplastic neuropathy",
      "features": "Subacute multifocal neuropathy; weight loss; smoking history; may have vasculitis on biopsy",
      "tests": "Paraneoplastic antibody panel; CT/PET for occult malignancy"
    }
  ],
  "evidence": [
    {
      "recommendation": "Combined nerve and muscle biopsy has highest sensitivity (~80%) for vasculitic neuropathy diagnosis",
      "evidenceLevel": "Class IIa, Level B",
      "source": "[Collins MP et al. Neurology 2010](https://pubmed.ncbi.nlm.nih.gov/21135380/)"
    },
    {
      "recommendation": "Rituximab non-inferior to cyclophosphamide for AAV induction (RAVE trial)",
      "evidenceLevel": "Class I, Level A",
      "source": "[Stone JH et al. N Engl J Med 2010](https://pubmed.ncbi.nlm.nih.gov/20647199/)"
    },
    {
      "recommendation": "Cyclophosphamide remains standard induction for severe vasculitic neuropathy",
      "evidenceLevel": "Class I, Level A",
      "source": "[de Groot K et al. Ann Intern Med 2009](https://pubmed.ncbi.nlm.nih.gov/19805771/)"
    },
    {
      "recommendation": "NSVN requires less aggressive immunosuppression than systemic vasculitis",
      "evidenceLevel": "Class IIa, Level C",
      "source": "[Collins MP et al. Neurology 2010](https://pubmed.ncbi.nlm.nih.gov/21135380/)"
    },
    {
      "recommendation": "Prednisone + azathioprine effective maintenance for vasculitic neuropathy",
      "evidenceLevel": "Class IIa, Level B",
      "source": "[Jayne D et al. N Engl J Med 2003](https://pubmed.ncbi.nlm.nih.gov/12840090/)"
    },
    {
      "recommendation": "Rituximab maintenance prevents relapse in AAV (MAINRITSAN trial)",
      "evidenceLevel": "Class I, Level A",
      "source": "[Guillevin L et al. N Engl J Med 2014](https://pubmed.ncbi.nlm.nih.gov/25372085/)"
    },
    {
      "recommendation": "Peripheral Nerve Society guideline on classification and diagnosis of vasculitic neuropathy",
      "evidenceLevel": "Guideline",
      "source": "[Collins MP et al. J Peripher Nerv Syst 2010](https://pubmed.ncbi.nlm.nih.gov/21199100/)"
    },
    {
      "recommendation": "PAN associated with hepatitis B; antiviral therapy is first-line for HBV-PAN",
      "evidenceLevel": "Class IIa, Level B",
      "source": "[Trepo C, Guillevin L. Medicine 2016](https://pubmed.ncbi.nlm.nih.gov/27472721/)"
    },
    {
      "recommendation": "Plasma exchange for severe renal vasculitis (PEXIVAS trial — nuanced benefit)",
      "evidenceLevel": "Class I, Level A",
      "source": "[Walsh M et al. N Engl J Med 2020](https://pubmed.ncbi.nlm.nih.gov/32053298/)"
    }
  ],
  "monitoring": [
    {
      "item": "CBC with differential",
      "frequency": "Q1-2wk during induction; monthly during maintenance",
      "action": "Hold cytotoxic agent if WBC <4000 or ANC <1500; G-CSF if severe neutropenia",
      "ED": "STAT",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "STAT"
    },
    {
      "item": "ESR / CRP",
      "frequency": "Each visit",
      "action": "If rising, assess for disease flare vs infection",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Renal function (BUN, Cr, UA)",
      "frequency": "Q2wk during induction; monthly maintenance",
      "action": "Nephrology reassessment; adjust immunosuppression; evaluate for renal flare",
      "ED": "STAT",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "STAT"
    },
    {
      "item": "ANCA titers (PR3 or MPO)",
      "frequency": "Q3-6 months if AAV; baseline at diagnosis",
      "action": "Rising titers may precede clinical flare; intensify monitoring; obtain baseline in newly diagnosed inpatients",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Hepatic function (LFTs)",
      "frequency": "Monthly during immunosuppression",
      "action": "Dose-reduce or hold hepatotoxic agent; evaluate for drug-induced liver injury",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Urinalysis with microscopy",
      "frequency": "Q1-2wk during induction; monthly maintenance",
      "action": "Urgent nephrology evaluation for new active sediment",
      "ED": "STAT",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "STAT"
    },
    {
      "item": "Blood glucose / HbA1c",
      "frequency": "Q3 months on steroids",
      "action": "Add or intensify glucose-lowering therapy",
      "ED": "-",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "NCS/EMG",
      "frequency": "Q6-12 months or if new symptoms",
      "action": "Reassess treatment; evaluate for disease progression or new nerve infarction",
      "ED": "-",
      "HOSP": "-",
      "OPD": "ROUTINE",
      "ICU": "-"
    },
    {
      "item": "Strength and sensory examination",
      "frequency": "Each visit",
      "action": "Treatment adjustment; evaluate for disease flare",
      "ED": "STAT",
      "HOSP": "ROUTINE",
      "OPD": "ROUTINE",
      "ICU": "-"
    }
  ],
  "disposition": [
    {
      "disposition": "Discharge from ED",
      "criteria": "Stable neuropathy without acute progression; outpatient rheumatology and neurology follow-up arranged; no systemic organ involvement requiring urgent intervention"
    },
    {
      "disposition": "Admit to floor",
      "criteria": "Rapidly progressive neuropathy with new weakness; suspected systemic vasculitis with organ involvement (renal, pulmonary); need for IV pulse steroids or cyclophosphamide; nerve biopsy planning"
    },
    {
      "disposition": "Admit to ICU",
      "criteria": "Pulmonary hemorrhage; rapidly progressive glomerulonephritis with dialysis need; severe multiorgan vasculitis; respiratory failure from neuromuscular weakness"
    },
    {
      "disposition": "Outpatient follow-up (rheumatology)",
      "criteria": "All patients: q2-4 weeks during induction; q1-3 months during maintenance; immunosuppression monitoring and taper guidance"
    },
    {
      "disposition": "Outpatient follow-up (neurology)",
      "criteria": "All patients: q3-6 months for NCS/EMG monitoring, pain management, and functional assessment"
    }
  ]
}